{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":53,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":53,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"c4752fabaa7c","filters":{"venue":"BioDrugs"}},"results":[{"id":"W2277879584","doi":"10.1007/s40259-016-0162-9","title":"Trastuzumab in the Treatment of Breast Cancer","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Norwegian Institute of Public Health; Direktorat Jenderal Pendidikan Tinggi; Sanofi Pasteur; Johns Hopkins Bloomberg School of Public Health; University of Illinois at Urbana-Champaign; National Institutes of Health; Seqirus; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja; Ministero della Salute; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Bundesministerium für Bildung und Forschung; Novavax; Sanofi; Comunidad de Madrid; Boston Scientific Corporation; Public Health England; University of Calgary; Arizona State University; GlaxoSmithKline; Bristol-Myers Squibb; Australian Government; Pfizer; Lembaga Pengelola Dana Pendidikan; Johns Hopkins University; Edwards Lifesciences; Bill and Melinda Gates Foundation; Instituto de Salud Carlos III; Amgen; Damon Runyon Cancer Research Foundation; Medical Research Council; Teva Pharmaceutical Industries; South African Medical Research Council; Seoul National University; U.S. Department of Veterans Affairs; Genentech; U.S. Environmental Protection Agency","keywords":"Trastuzumab; Pertuzumab; Medicine; Lapatinib; Breast cancer; Cardiotoxicity; Cancer; Disease; Oncology; Targeted therapy; Internal medicine; Pharmacology; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1386676677073322,"gpt":0.4761857603569551,"spread":0.337518092649623,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002709988,0.000286609,0.00133965,0.0002082659,0.00002051484,0.000009270268,0.0002733549,0.0001937033,0.0009609775],"category_scores_gemma":[0.00001375853,0.0001211273,0.0004157675,0.0003961801,0.0001363078,0.00001516205,0.00001839126,0.0001755761,0.000181515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001176393,"about_ca_system_score_gemma":0.001498315,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008009699,"about_ca_topic_score_gemma":0.0000817705,"domain_scores_codex":[0.9982003,0.0001948761,0.0004685401,0.0003194583,0.000474715,0.0003420959],"domain_scores_gemma":[0.9988558,0.0002162451,0.0001409006,0.0006444168,0.00005677595,0.00008586198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002427761,0.0002928599,0.00006555648,0.00612644,0.0001238975,0.00004234898,0.0002972211,3.522457e-9,0.000001443212,0.00001872783,0.0027339,0.9902733],"study_design_scores_gemma":[0.00065193,0.0002782591,0.0002536422,0.01918188,0.0002885461,0.0001066575,0.00003434062,1.205675e-7,0.000005437065,0.000003411,0.9790844,0.0001113181],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004060407,0.9943005,4.127287e-7,0.0009333187,0.0001642857,0.00155378,0.0006801721,0.00001205815,0.002314832],"genre_scores_gemma":[0.00008853808,0.9966168,0.0000101897,0.00003887924,0.0005385281,0.0007628117,0.00002769195,0.00004010699,0.00187644],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.990162,"threshold_uncertainty_score":0.9999523,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2079402257","doi":"10.2165/00063030-200115050-00001","title":"C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral??* Formulation","year":2001,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Immunosuppression; Medicine; Therapeutic drug monitoring; Nephrotoxicity; Trough level; Transplantation; Kidney transplantation; Urology; Ciclosporin; Pharmacology; Internal medicine; Drug; Kidney; Tacrolimus","retraction":null,"screen_n_in":null,"score":{"opus":0.2002765864096752,"gpt":0.4437927799303807,"spread":0.2435161935207055,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002548377,0.0003976188,0.001197011,0.00004920045,0.0003017905,0.00005969716,0.0001920394,0.0002989445,0.00004765042],"category_scores_gemma":[0.0001247811,0.0002049587,0.0005330081,0.0001974954,0.00004445257,0.00007625628,0.0001057538,0.0003940481,0.00002125799],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001510256,"about_ca_system_score_gemma":0.00008131467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008685273,"about_ca_topic_score_gemma":6.333186e-7,"domain_scores_codex":[0.9984723,0.00008731545,0.0004876614,0.0003847856,0.00022019,0.0003477049],"domain_scores_gemma":[0.9984027,0.0008477706,0.0002935636,0.0002981224,0.0000671996,0.00009062295],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006291521,0.00006719216,0.0000383644,0.001777532,0.0002803494,0.00001333796,0.0000428656,0.000005570345,0.00006501059,0.00001699772,0.001412378,0.9962175],"study_design_scores_gemma":[0.0007276773,0.0001713976,0.0003074372,0.009287932,0.001670368,0.00001061994,0.00005662231,0.00007146966,0.0001135877,0.00008095541,0.9872467,0.000255224],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007223913,0.9955134,0.0001238374,0.0002069262,0.0006887214,0.002088272,0.00009911593,0.00009095393,0.0004664195],"genre_scores_gemma":[0.001650671,0.994686,0.0006273458,0.00006128812,0.002036908,0.0002045104,0.0002731669,0.00004331882,0.0004168094],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9959623,"threshold_uncertainty_score":0.8357974,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2016399234","doi":"10.2165/00063030-200923010-00002","title":"MicroRNA-Based Therapeutics for Cancer","year":2009,"lang":"en","type":"review","venue":"BioDrugs","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":159,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"microRNA; Biology; Translation (biology); Oncomir; Cancer; Signal transduction; Computational biology; Cancer research; Bioinformatics; Gene; Messenger RNA; Cell biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.04809701016503418,"gpt":0.3556908438159273,"spread":0.3075938336508931,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009969129,0.0003489141,0.0005284014,0.00006493483,0.00005865751,0.0000303742,0.0002804858,0.0004695181,0.00001940176],"category_scores_gemma":[0.00001266586,0.0003012086,0.000597664,0.00009093767,0.00004530081,0.00000101982,0.00002851417,0.00007348973,0.00001598933],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006287766,"about_ca_system_score_gemma":0.0005838501,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003504141,"about_ca_topic_score_gemma":0.00000578394,"domain_scores_codex":[0.998815,0.00005775541,0.0003192117,0.0004572803,0.00008733493,0.0002633956],"domain_scores_gemma":[0.9990866,0.00001729052,0.0002576661,0.0004805819,0.00008952681,0.00006837271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001907324,0.00004885496,9.802221e-7,0.002972804,0.0001692691,4.455824e-7,0.000002237603,0.000002060791,0.004670968,0.000009887569,0.006841391,0.985262],"study_design_scores_gemma":[0.0002418058,0.00005679125,0.000002959658,0.001092497,0.0006082106,0.000002234892,7.708053e-7,0.000006015689,0.003847161,0.000009459916,0.9937732,0.0003589482],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002532435,0.9975163,0.0005745248,0.00006722614,0.0002188636,0.0009699858,0.0005433763,0.00001966475,0.00006475025],"genre_scores_gemma":[0.00001948823,0.9950333,0.0009397689,0.0004071195,0.0006692092,0.0002633851,0.002024778,0.00006887394,0.0005741075],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9869317,"threshold_uncertainty_score":0.999944,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2550419061","doi":"10.1007/s40259-016-0204-3","title":"Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Ontario Institute for Cancer Research","keywords":"Immune system; Immunology; Medicine; Adverse effect; Autoimmunity; Immunotherapy; Antibody; Immune checkpoint; Cytotoxic T cell; CTLA-4; Nivolumab; T cell; Biology; Pharmacology","retraction":null,"screen_n_in":null,"score":{"opus":0.01959998934634755,"gpt":0.2869797453921792,"spread":0.2673797560458316,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000787278,0.0008202319,0.002508029,0.0003630065,0.000130507,0.00001127893,0.0003057439,0.0008357855,0.0009379983],"category_scores_gemma":[0.0001225724,0.0004758021,0.001809522,0.0008329203,0.0002341152,0.00009572685,0.00009680582,0.0005966078,0.0006209209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001026994,"about_ca_system_score_gemma":0.0009373314,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001009704,"about_ca_topic_score_gemma":0.000005051386,"domain_scores_codex":[0.9962163,0.0002093725,0.001720878,0.0006617326,0.0005659453,0.0006257722],"domain_scores_gemma":[0.9973187,0.0001279167,0.001355601,0.0008737987,0.0001421879,0.0001817677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006907583,0.000398227,0.00006134583,0.004492113,0.005795133,0.000127913,0.0001450078,1.58079e-8,0.0003118791,0.000007504169,0.0009730743,0.986997],"study_design_scores_gemma":[0.004549214,0.0003779545,0.0004614578,0.09405254,0.001718815,0.0001370496,0.00003061095,2.443073e-7,0.0001566562,0.000004643272,0.8978357,0.0006751343],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005458122,0.994088,0.000001615656,0.0001802305,0.00101807,0.001762855,0.0001527008,0.0002286582,0.002022059],"genre_scores_gemma":[0.0004172738,0.9841294,0.00002358003,0.00005259792,0.000182271,0.0001399863,0.0006527184,0.000168749,0.01423347],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9863219,"threshold_uncertainty_score":0.9999753,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2896685834","doi":"10.1007/s40259-018-0309-y","title":"Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier","year":2018,"lang":"en","type":"article","venue":"BioDrugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":103,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"National Research Council Canada","funders":"Government of Canada","keywords":"Transcytosis; Biomanufacturing; Gene delivery; Blood–brain barrier; Transferrin receptor; Genetic enhancement; Nanocarriers; Medicine; Biology; Neuroscience; Computational biology; Immunology; Receptor; Central nervous system; Gene; Pharmacology; Drug; Biotechnology","retraction":null,"screen_n_in":null,"score":{"opus":0.01483342197156779,"gpt":0.2858330559010852,"spread":0.2709996339295174,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001642282,0.000113025,0.00009984998,0.00002164205,0.0001323962,0.00001993325,0.0002237654,0.0001324084,0.000005321326],"category_scores_gemma":[0.00002996167,0.0000765369,0.00006589569,0.00005940653,0.0004108208,0.000003212782,0.00009568508,0.0000361936,0.00000159303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000002012287,"about_ca_system_score_gemma":0.00002565878,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001805281,"about_ca_topic_score_gemma":0.00001815857,"domain_scores_codex":[0.9993774,0.00001733366,0.0001395815,0.0002156403,0.00005564066,0.0001944093],"domain_scores_gemma":[0.9994746,0.00002247394,0.00006512977,0.0002992832,0.000121541,0.00001695935],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00009729505,0.00001863707,0.0008733839,0.000005882279,0.00009718465,1.646466e-7,0.0002860588,2.678154e-7,0.9469309,0.00003061585,0.0009580653,0.05070156],"study_design_scores_gemma":[0.0003975071,0.0005139336,0.0002952224,0.000006194078,0.00001010321,0.00000444274,0.0007084121,0.00002440451,0.9013749,0.000100503,0.09646425,0.0001000587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924968,0.005685263,0.0006554214,0.0007453362,0.0001030081,0.0001784822,0.00007997517,0.00001695095,0.00003869742],"genre_scores_gemma":[0.995881,0.002276954,0.0006348263,0.0006757617,0.0001468843,0.00002155786,0.00001390425,0.00001332344,0.0003358062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09550619,"threshold_uncertainty_score":0.3121084,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3094124122","doi":"10.1007/s40259-020-00451-w","title":"Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease","year":2020,"lang":"en","type":"article","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":100,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ministère de l'Agriculture, des Pêcheries et de l'Alimentation; University of Calgary; Western University","funders":"","keywords":"Ustekinumab; Medicine; Interleukin 23; Ulcerative colitis; Inflammatory bowel disease; Crohn's disease; Immunology; Inflammation; Immune system; Pathogenesis; Disease; Clinical trial; Interleukin 17; Internal medicine; Tumor necrosis factor alpha; Infliximab","retraction":null,"screen_n_in":null,"score":{"opus":0.06456502656389661,"gpt":0.3167934866840165,"spread":0.2522284601201198,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001353864,0.0001935845,0.0006224097,0.00009388576,0.00004356076,0.000007255415,0.0001912303,0.000288547,0.0002583255],"category_scores_gemma":[0.001142285,0.0001587007,0.0003906072,0.0001194763,0.0001792186,0.00006038081,0.00008374306,0.0001662124,0.0006888841],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001891496,"about_ca_system_score_gemma":0.0001527443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001709602,"about_ca_topic_score_gemma":0.000007759669,"domain_scores_codex":[0.9970355,0.001153194,0.001162622,0.0003502157,0.00004539026,0.000253086],"domain_scores_gemma":[0.9987401,0.0005484394,0.0003354576,0.0002498316,0.00002897925,0.00009717769],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003357326,0.0005242595,0.8506994,0.0001148319,0.0004976017,0.00007480324,0.001186258,0.000003218536,0.06332503,0.0003426446,0.02036804,0.05950662],"study_design_scores_gemma":[0.01343144,0.0005261569,0.7222704,0.0001681492,0.0005488481,0.000003108903,0.0005552023,0.00001011065,0.08469117,0.0001566698,0.1770248,0.0006138656],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935011,0.003214715,0.000004483635,0.0009447747,0.001138358,0.0003761364,0.0004461487,0.00005995662,0.0003142895],"genre_scores_gemma":[0.9984897,0.000333271,0.00003642526,0.0002835952,0.0002337877,0.00003028455,0.0001815584,0.000015663,0.0003957514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1566568,"threshold_uncertainty_score":0.885444,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3212746417","doi":"10.1007/s40259-021-00507-5","title":"Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":77,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; American Gastroenterological Association","keywords":"Medicine; Inflammatory bowel disease; Drug; Meta-analysis; Antibody; Pharmacotherapy; Pharmacology; Disease; Immunology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04189853835288371,"gpt":0.331977762686112,"spread":0.2900792243332283,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001052039,0.0008137448,0.004585075,0.0003992638,0.00009299056,0.0001123949,0.0005002567,0.0003365933,0.00006578815],"category_scores_gemma":[0.0003558497,0.0006015747,0.002933607,0.0005539832,0.00009970093,0.00002079003,0.0003764054,0.0002193105,0.00005633563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007026498,"about_ca_system_score_gemma":0.0003149579,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002365088,"about_ca_topic_score_gemma":0.00001159703,"domain_scores_codex":[0.9951579,0.001465141,0.001683131,0.0009593282,0.000301626,0.0004328633],"domain_scores_gemma":[0.9970943,0.00003933084,0.00105074,0.001382259,0.0001464185,0.0002868983],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.000003942401,0.00007261027,0.0001197306,0.9610371,0.03735416,0.0003297676,0.0000137196,0.000004404616,0.000005647896,0.00001698095,0.0008455373,0.0001963992],"study_design_scores_gemma":[0.0002337059,0.0000107826,0.0004753682,0.0423772,0.8634329,0.0000190737,0.00002583615,0.00002297036,0.000003360541,0.000002381039,0.09211858,0.001277769],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004740101,0.9955519,0.00001395472,0.00003739921,0.0000515903,0.003105385,0.0006876076,0.00002804421,0.00005004775],"genre_scores_gemma":[0.0003476245,0.9903569,0.0000292358,0.0006301192,0.00004220019,0.0008579328,0.007321736,0.0000549586,0.0003592633],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9186599,"threshold_uncertainty_score":0.9996436,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1965655787","doi":"10.2165/00063030-200519010-00004","title":"Pharmacologic Approaches to the Treatment of Amyotrophic Lateral Sclerosis","year":2005,"lang":"en","type":"review","venue":"BioDrugs","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Riluzole; Amyotrophic lateral sclerosis; Glial cell line-derived neurotrophic factor; SOD1; Excitotoxicity; Neurodegeneration; Neurotrophic factors; Medicine; Oxidative stress; Neuroprotection; Pharmacology; Vascular endothelial growth factor; Glutamate receptor; Biology; Disease; Pathology; Cancer research; Internal medicine; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.5004309636387372,"gpt":0.4003231433586333,"spread":0.1001078202801039,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002640594,0.0006032028,0.002115252,0.0002829357,0.0001143064,0.00003986353,0.0004924303,0.0003444953,0.0006279293],"category_scores_gemma":[0.00002216777,0.0002877824,0.0009905406,0.0007132508,0.0001926272,0.00003954754,0.0001364238,0.0003356125,0.0009358005],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007227728,"about_ca_system_score_gemma":0.0003131818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009453001,"about_ca_topic_score_gemma":0.000006344277,"domain_scores_codex":[0.9970258,0.0003050042,0.000781184,0.0006468235,0.0005962113,0.0006449126],"domain_scores_gemma":[0.9983652,0.0001379282,0.0002511079,0.0008410857,0.00006327627,0.0003414096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006743216,0.0006126748,0.00001581393,0.001865332,0.0005053112,0.00001335109,0.0002210576,0.000002468274,0.00003028211,0.00001773772,0.001920167,0.9947284],"study_design_scores_gemma":[0.0007226206,0.001109972,0.0004724243,0.002662127,0.001332096,0.00002743848,0.000007079207,0.00001464684,0.00002569539,0.000001778731,0.9933637,0.0002603962],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002349851,0.9910279,0.000002053437,0.002208906,0.0001980501,0.003548777,0.000123834,0.00006677851,0.0004738562],"genre_scores_gemma":[0.0017486,0.9921564,0.0003652835,0.0001847506,0.001213461,0.0008539257,0.0001130411,0.00008007082,0.003284488],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.994468,"threshold_uncertainty_score":0.9999574,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W137417466","doi":"10.2165/00063030-200519010-00005","title":"Antibody Induction Therapy in Renal Transplant Patients Receiving Calcineurin-Inhibitor Immunosuppressive Regimens","year":2005,"lang":"en","type":"review","venue":"BioDrugs","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Medicine; Basiliximab; Daclizumab; Thymoglobulin; Calcineurin; Immunology; Internal medicine; Transplantation; Gastroenterology; Tacrolimus","retraction":null,"screen_n_in":null,"score":{"opus":0.04379392079459723,"gpt":0.3572671704822917,"spread":0.3134732496876945,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001201968,0.0005908476,0.00155202,0.000470006,0.00007459424,0.00003063388,0.0001391062,0.0004015265,0.00009248483],"category_scores_gemma":[0.00001173477,0.0004096856,0.0005456142,0.0003842158,0.0000465144,0.0001264173,0.00001285647,0.0005318599,0.0001101292],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002528703,"about_ca_system_score_gemma":0.0001826561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007156649,"about_ca_topic_score_gemma":0.000007782838,"domain_scores_codex":[0.9974969,0.0001734112,0.0009126515,0.0005975973,0.0004144027,0.0004050187],"domain_scores_gemma":[0.9989091,0.000101038,0.0003761414,0.0003979451,0.0000718948,0.0001439012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002445855,0.0007544858,0.003688534,0.003630216,0.0005013567,0.0002910834,0.0004925989,5.253085e-7,0.00007104014,0.000004899421,0.00006345756,0.9902572],"study_design_scores_gemma":[0.007867794,0.0007028851,0.0213449,0.06625071,0.001223503,0.0003546081,0.00001575329,0.000001462086,0.0001895068,0.000002251111,0.9013361,0.0007105699],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006637551,0.9897069,0.000006959304,0.00006175387,0.0006173269,0.001881271,0.0002490366,0.00007009961,0.0007691318],"genre_scores_gemma":[0.00261679,0.9914522,0.0001523085,0.00005958078,0.0003606015,0.0001041022,0.004442061,0.00007872747,0.0007336444],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9895467,"threshold_uncertainty_score":0.9998355,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052842550","doi":"10.2165/00063030-200115120-00005","title":"Current and Future Applications of Immunological Attenuation via Pegylation of Cells and Tissue","year":2001,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Transplantation; PEGylation; Immune system; Immunology; Immunosuppression; Immunogenicity; Immunologic Tolerance; Antigenicity; Alloimmunity; Antibody; Medicine; In vivo; Immune tolerance; Cancer research; Biology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0297655885367215,"gpt":0.3219776703747264,"spread":0.2922120818380048,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009604036,0.0001368806,0.0007029363,0.0001216188,0.00002181061,0.000003598214,0.00002911802,0.0001726843,0.00008321461],"category_scores_gemma":[0.0000151405,0.00009789688,0.00006678989,0.0002111716,0.00008681405,0.0000194957,0.00002115844,0.0001082722,0.00001000241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001840545,"about_ca_system_score_gemma":0.00004332038,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006487661,"about_ca_topic_score_gemma":1.651793e-7,"domain_scores_codex":[0.999249,0.00003959309,0.0003570221,0.0001751017,0.0001074962,0.00007179091],"domain_scores_gemma":[0.9993441,0.00008334175,0.0002804735,0.000170124,0.00007525935,0.00004671208],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000005441001,0.00005777424,0.00006428573,0.005748699,0.00003433491,1.381399e-7,0.00002572124,6.434107e-9,0.0002554269,0.00009304507,0.0001252705,0.9935899],"study_design_scores_gemma":[0.0002423046,0.00008524218,0.0004723095,0.001298328,0.0006156414,0.00001172047,0.00002504932,0.000003843858,0.0001532695,0.00002360109,0.9969922,0.00007647168],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004207067,0.9979688,0.0003283874,0.00004248115,0.00009533063,0.000715339,0.00004184635,0.00001397565,0.0003731212],"genre_scores_gemma":[0.0001982311,0.9988031,0.0003581841,0.0000064075,0.0002117,0.00005863351,0.0002344642,0.000008090254,0.0001211297],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9968669,"threshold_uncertainty_score":0.3992119,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W183087027","doi":"10.2165/00063030-200418050-00004","title":"Islet Transplantation in Patients with Diabetes Mellitus","year":2004,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pancreatic function and diabetes","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Immunosuppression; Transplantation; Azathioprine; Diabetes mellitus; Tacrolimus; Sirolimus; Type 1 diabetes; Insulin; Islet; Everolimus; Organ transplantation; Immunology; Intensive care medicine; Internal medicine; Endocrinology; Disease","retraction":null,"screen_n_in":null,"score":{"opus":0.01529438150529137,"gpt":0.2579263903664687,"spread":0.2426320088611774,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008462343,0.000288675,0.001081114,0.0002582317,0.00002136656,0.0000133622,0.0000570543,0.0001963315,0.0001244028],"category_scores_gemma":[0.00002519622,0.0001886288,0.0001524993,0.0003375241,0.00004437539,0.0000463236,0.000005450978,0.0001953488,0.0001993636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001617212,"about_ca_system_score_gemma":0.0002403399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001190747,"about_ca_topic_score_gemma":9.352783e-7,"domain_scores_codex":[0.9988059,0.00004586285,0.0003625978,0.00029409,0.0002450584,0.000246473],"domain_scores_gemma":[0.9994276,0.00007707076,0.0001290085,0.000225916,0.00004125382,0.00009921446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009835164,0.0005186622,0.01121861,0.06890003,0.0002698429,0.00002317269,0.0001471863,4.492682e-7,5.47616e-7,0.00006811567,0.0002907984,0.9184642],"study_design_scores_gemma":[0.004442223,0.0004501291,0.005908156,0.05663308,0.001959737,0.000002615095,0.000008123702,6.199408e-7,0.00001940082,0.0000146404,0.9301366,0.0004246281],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005120635,0.99217,0.000003205912,0.00001942145,0.0001398189,0.0008788001,0.00008571464,0.00005251416,0.001529837],"genre_scores_gemma":[0.0004227855,0.9974106,0.0002025375,0.0001064414,0.00006605587,0.00008113845,0.001454546,0.00003686019,0.0002190354],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9298459,"threshold_uncertainty_score":0.7692059,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2131592861","doi":"10.1007/s40259-015-0130-9","title":"Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital","funders":"Boehringer Ingelheim","keywords":"Afatinib; Erlotinib; Gefitinib; Epidermal growth factor receptor; Lung cancer; Medicine; Oncology; Cetuximab; Internal medicine; EGFR inhibitors; Cancer research; Tyrosine kinase; Pharmacology; Cancer; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.1326961338418439,"gpt":0.3950047831603708,"spread":0.2623086493185269,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001889923,0.0003551209,0.0009612228,0.0003661665,0.00005247038,0.000037933,0.00008031391,0.0002504212,0.00009735123],"category_scores_gemma":[0.00004665912,0.000263131,0.0002686385,0.0004294085,0.00003237079,0.00007846375,0.00002991679,0.0002460043,0.000465284],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001135817,"about_ca_system_score_gemma":0.001111391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002514551,"about_ca_topic_score_gemma":0.00004908415,"domain_scores_codex":[0.9984021,0.00009172167,0.0004823362,0.0004396194,0.0003366822,0.0002475418],"domain_scores_gemma":[0.9990993,0.00004366313,0.0002047447,0.0003819755,0.00008352136,0.0001867677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001534408,0.0002928608,0.00001479744,0.001690204,0.0001222159,0.00007306559,0.0001826577,9.716535e-7,0.000002955832,0.0001292491,0.02939402,0.9680817],"study_design_scores_gemma":[0.001403116,0.0002746443,0.00000997191,0.007694802,0.001072514,0.00001660183,0.00005156274,0.000006790677,0.00002583979,0.00001573069,0.9891906,0.0002378365],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001037964,0.9884511,0.000002810821,0.0003304755,0.0008740815,0.001708878,0.0001135804,0.00004946275,0.008365826],"genre_scores_gemma":[0.0004653912,0.9938689,0.0002229209,0.0001219506,0.0007881919,0.00030518,0.00115331,0.00005321548,0.003020886],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9678438,"threshold_uncertainty_score":0.9999821,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1778153929","doi":"10.1007/s40259-015-0144-3","title":"Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; SKiN Health","funders":"","keywords":"Apremilast; Psoriasis; Medicine; Proinflammatory cytokine; Pharmacology; Tumor necrosis factor alpha; Immunology; Tofacitinib; Phosphodiesterase; Inflammation; Psoriatic arthritis; Rheumatoid arthritis; Chemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.0367836431140947,"gpt":0.3169684356943395,"spread":0.2801847925802448,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002965605,0.0005604554,0.00085985,0.0001299254,0.0001288402,0.00005219554,0.0002133229,0.0006760303,0.000008240345],"category_scores_gemma":[0.0001303063,0.0004466939,0.000596988,0.0001889149,0.00007106714,0.000004908491,0.00008845295,0.0001801334,0.00007994648],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001487113,"about_ca_system_score_gemma":0.0004196766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007772774,"about_ca_topic_score_gemma":0.00001014118,"domain_scores_codex":[0.9980489,0.0001179776,0.000502439,0.0007656638,0.0002103879,0.0003546232],"domain_scores_gemma":[0.9986781,0.0000470604,0.0003583811,0.0005084896,0.0002284611,0.0001794809],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002365489,0.0001207428,0.000002221183,0.001542882,0.000292459,0.000001346071,0.00005153038,0.000003449467,0.00008794056,0.00005997056,0.1521504,0.8454505],"study_design_scores_gemma":[0.0006944996,0.0005143745,0.00000111534,0.001264296,0.000275447,0.00001242264,0.00002402255,0.000002237181,0.00350041,0.00005681586,0.9931316,0.000522776],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004654637,0.994369,0.0001757197,0.0000416778,0.001943651,0.001450441,0.0003610745,0.00004956439,0.001562278],"genre_scores_gemma":[0.0002243368,0.9915223,0.0002085774,0.0001344801,0.001866382,0.0006428736,0.00174196,0.0001121034,0.003547033],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8449277,"threshold_uncertainty_score":0.9997985,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015187915","doi":"10.2165/00063030-200822040-00002","title":"Strategies Toward the Improved Oral Delivery of Insulin Nanoparticles via Gastrointestinal Uptake and Translocation","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Advanced Drug Delivery Systems","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":67,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Insulin; Glycemic; Gastrointestinal tract; Nanoparticle; Diabetes mellitus; Nanotechnology; Pharmacology; Medicine; Chemistry; Materials science; Internal medicine; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.1589632605650296,"gpt":0.4157631336086455,"spread":0.2567998730436158,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004089326,0.0004595673,0.001047032,0.0001092597,0.0001720303,0.00002319084,0.0003738986,0.0004232282,0.00006285225],"category_scores_gemma":[0.00003410289,0.0003224942,0.000257025,0.0002691129,0.0006122992,0.0001662509,0.00007176539,0.000945627,0.00005761446],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006329182,"about_ca_system_score_gemma":0.00040728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007709486,"about_ca_topic_score_gemma":0.00002603593,"domain_scores_codex":[0.9974254,0.0006848294,0.000935242,0.0004085081,0.0001558506,0.0003901868],"domain_scores_gemma":[0.9984193,0.0004773962,0.0005704849,0.0002532661,0.0001455285,0.0001339935],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000963452,0.0001070037,0.00001670536,0.002718164,0.0001742291,0.00001800745,0.0006967154,0.00002658746,0.001861975,0.0001401285,0.0003419726,0.9938022],"study_design_scores_gemma":[0.0007313102,0.0001870556,0.00002825798,0.001275951,0.000566077,0.0008736476,0.0006233162,0.001118362,0.0004972541,0.0000332498,0.9936705,0.0003949996],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003509006,0.9940527,0.0005231654,0.00009379741,0.0004056621,0.00110051,0.0001659836,0.00007176468,0.00007741545],"genre_scores_gemma":[0.03348166,0.9654304,0.0005986194,0.00007302516,0.0001585561,0.000110317,0.00005643729,0.00003994425,0.00005106208],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9934072,"threshold_uncertainty_score":0.9999227,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4402620082","doi":"10.1007/s40259-024-00677-y","title":"Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure","year":2024,"lang":"en","type":"review","venue":"BioDrugs","topic":"Mosquito-borne diseases and control","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences","keywords":"Chikungunya; Medicine; Clinical trial; European union; Virology; Alphavirus; Licensure; Virus; Internal medicine; Business","retraction":null,"screen_n_in":null,"score":{"opus":0.0731524147698617,"gpt":0.4688754399647942,"spread":0.3957230251949325,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001335483,0.0005048304,0.003169461,0.0001521721,0.0000297335,0.00003122095,0.0002181676,0.0003466257,0.0009142785],"category_scores_gemma":[0.001156431,0.0003369094,0.001090373,0.0004082919,0.00003295916,0.00003871114,0.0001728483,0.0004118008,0.0003854537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006772573,"about_ca_system_score_gemma":0.0008305762,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001450715,"about_ca_topic_score_gemma":0.00001418606,"domain_scores_codex":[0.9962667,0.0003886295,0.001571072,0.0008799249,0.0006230987,0.0002705423],"domain_scores_gemma":[0.9976386,0.0002771861,0.0004643842,0.0009608016,0.0002624342,0.0003965327],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005510291,0.0001119331,0.00002410453,0.1198895,0.0006266424,0.00001159142,0.00002818257,5.302696e-9,9.000789e-7,0.00001168505,0.0348209,0.8444195],"study_design_scores_gemma":[0.00056726,0.0001894719,0.0005674234,0.213074,0.02536358,0.00001130198,0.000005367869,0.00002088602,2.663348e-7,0.00001388703,0.7599589,0.0002276186],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001660795,0.9929573,0.000004182479,0.0004526451,0.0006571364,0.004423002,0.0008620782,0.00005513519,0.0004224754],"genre_scores_gemma":[0.00004008218,0.9951527,0.00009870235,0.001434976,0.00145463,0.0004137593,0.0007786083,0.00007025083,0.0005562678],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8441918,"threshold_uncertainty_score":0.999999,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2047330433","doi":"10.2165/00063030-200923020-00002","title":"Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy","year":2009,"lang":"en","type":"review","venue":"BioDrugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"Howard Hughes Medical Institute","keywords":"PI3K/AKT/mTOR pathway; Sirolimus; Protein kinase B; Cancer; Cancer research; RPTOR; Signal transduction; Pharmacology; Biology; Medicine; Internal medicine; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.07859009767915429,"gpt":0.3535119843236535,"spread":0.2749218866444992,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002578892,0.0004559327,0.0007832593,0.00005498421,0.00008761962,0.00003673463,0.0001976365,0.0003645263,0.000009814229],"category_scores_gemma":[0.00007406147,0.0003366555,0.0002089806,0.00008064106,0.00007242015,0.000002904204,0.000044131,0.0001723475,0.000001291355],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009652038,"about_ca_system_score_gemma":0.0005142633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001223639,"about_ca_topic_score_gemma":0.00002863247,"domain_scores_codex":[0.9982833,0.0001043831,0.000310445,0.0006715255,0.0001550226,0.0004753436],"domain_scores_gemma":[0.9990401,0.00005838045,0.000378115,0.0002694622,0.0001359218,0.0001179936],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003382154,0.00004905296,0.00001541248,0.001670794,0.0003090326,5.279077e-7,0.00003708524,4.910814e-7,0.0000988918,0.000008640372,0.001948787,0.9958274],"study_design_scores_gemma":[0.0005332842,0.0003693032,0.00001629148,0.003112344,0.0001897517,0.000001254594,0.00001050944,0.000001038307,0.0002327621,0.00000790609,0.995052,0.0004735218],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003257045,0.9979364,0.00001713253,0.00005829522,0.0003571136,0.0008175416,0.0004147885,0.00002656082,0.00004643917],"genre_scores_gemma":[0.00009517086,0.9975908,0.0001404673,0.00005486176,0.00081819,0.0004235401,0.000687913,0.00007980369,0.0001091965],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9953539,"threshold_uncertainty_score":0.9999086,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2089502375","doi":"10.1007/s40259-012-0003-4","title":"Targeting Focal Adhesion Kinase in Fibrotic Diseases","year":2012,"lang":"en","type":"review","venue":"BioDrugs","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Fibrosis; Extracellular matrix; Focal adhesion; Medicine; Scleroderma (fungus); Pulmonary fibrosis; Idiopathic pulmonary fibrosis; Cancer research; Signal transduction; Pathology; Immunology; Biology; Lung; Cell biology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03822410845400634,"gpt":0.3191907090961403,"spread":0.280966600642134,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001631863,0.0004859341,0.00155902,0.0002879914,0.00006529221,0.00002669621,0.0001713409,0.000349598,0.0003527483],"category_scores_gemma":[0.0001071273,0.0003705793,0.000821284,0.0003101499,0.00007791616,0.0001085168,0.0001337637,0.0004074529,0.0005582136],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003101455,"about_ca_system_score_gemma":0.000367484,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005344372,"about_ca_topic_score_gemma":6.51983e-7,"domain_scores_codex":[0.9977971,0.0001588414,0.0006869338,0.0004760661,0.0003147102,0.0005663076],"domain_scores_gemma":[0.9988133,0.0001034452,0.0002046116,0.00039545,0.00004163046,0.0004415362],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005098186,0.0007362787,0.0002479794,0.08157779,0.0001034861,0.0005544884,0.00004772802,2.099799e-7,0.000009511552,0.0001171945,0.003931149,0.9121644],"study_design_scores_gemma":[0.0003002991,0.0004496191,0.00008217954,0.0380075,0.002120226,0.00005216504,0.00002686829,0.00001890694,7.805016e-7,0.000008952674,0.9585258,0.000406738],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004940218,0.9975375,0.000004806138,0.00004482129,0.0005812562,0.0009926446,0.0002590781,0.00008164767,0.0004488637],"genre_scores_gemma":[0.002211432,0.9944539,0.00009159878,0.00008399374,0.001402033,0.000128605,0.00104832,0.00008316837,0.0004969588],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9545946,"threshold_uncertainty_score":0.9998746,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2923414225","doi":"10.1007/s40259-019-00347-4","title":"PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Ovarian cancer; Medicine; Cancer; Oncology; Pharmacotherapy; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04552099282661187,"gpt":0.3574579287860135,"spread":0.3119369359594016,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007514173,0.0003597708,0.002198142,0.0001564808,0.00004850595,0.00001836566,0.0001902188,0.0001646376,0.0006656626],"category_scores_gemma":[0.00003624663,0.0002039332,0.0005021255,0.0004734563,0.0001847739,0.00004439505,0.0001061014,0.0003064881,0.00006844507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009613201,"about_ca_system_score_gemma":0.0002168233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000474952,"about_ca_topic_score_gemma":0.000001773351,"domain_scores_codex":[0.997992,0.0001982198,0.0008138081,0.0004063686,0.0003585641,0.0002309977],"domain_scores_gemma":[0.9983079,0.0001772681,0.0006494876,0.0007013631,0.00008497605,0.00007905112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000353744,0.00002075974,0.00001985787,0.2270212,0.00058563,0.000006651648,0.00006101324,1.827519e-8,2.10376e-7,0.0004813132,0.04659909,0.7251689],"study_design_scores_gemma":[0.001576214,0.00001885706,0.00000897431,0.2096782,0.002965371,0.00003358839,0.0000128048,0.000001468072,0.000001191452,0.00001714733,0.7855277,0.0001585224],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[8.314244e-7,0.984233,0.000004073631,0.0009943456,0.0004725369,0.002929526,0.00008215509,0.000032429,0.01125116],"genre_scores_gemma":[0.00000952736,0.9957137,0.0001112545,0.001047185,0.0003573751,0.0005329907,0.00006090033,0.00005304643,0.002114045],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7389286,"threshold_uncertainty_score":0.8316154,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2067292160","doi":"10.2165/11586210-000000000-00000","title":"Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohnʼs Disease with no Relapse After Switching to Adalimumab","year":2010,"lang":"en","type":"article","venue":"BioDrugs","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Alberta Innovates - Health Solutions","keywords":"Infliximab; Adalimumab; Medicine; Autoimmune hepatitis; Crohn's disease; Internal medicine; Disease; Gastroenterology; Inflammatory bowel disease; Tumor necrosis factor alpha; Hepatitis; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.004201924402870781,"gpt":0.2110650540486236,"spread":0.2068631296457528,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008078586,0.0002587694,0.0002993436,0.0001373128,0.00008070305,0.00005301805,0.0001261786,0.00007727322,0.0002852569],"category_scores_gemma":[0.00007399124,0.0001821054,0.00005856983,0.0003095691,0.00004030349,0.0002014079,0.0001072256,0.0004571096,0.0001199332],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009167691,"about_ca_system_score_gemma":0.0002837755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003481429,"about_ca_topic_score_gemma":0.0003296593,"domain_scores_codex":[0.9985904,0.00004336583,0.0002689382,0.0003543927,0.0003732426,0.000369729],"domain_scores_gemma":[0.998612,0.00002770302,0.00008078211,0.0006671978,0.0001410459,0.0004712791],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01751889,0.002081295,0.9363636,0.0002226584,0.0001536475,0.00110573,0.004846293,0.000002622286,0.02825041,0.0000398972,0.002111509,0.00730342],"study_design_scores_gemma":[0.004395982,0.001423754,0.9827101,0.000522401,0.0001229405,0.00002386712,0.0001841501,0.0001232248,0.0005974226,0.000006888238,0.009497955,0.0003912622],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972819,0.0001619077,0.00001537882,0.0009734984,0.0001372776,0.0007853765,0.00009684166,0.00007459843,0.000473241],"genre_scores_gemma":[0.9970121,0.00001428402,0.0005604232,0.001709912,0.00004790993,0.0001961219,0.00007515189,0.00004422656,0.000339846],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04634652,"threshold_uncertainty_score":0.7426042,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W34856137","doi":"10.2165/0063030-200822060-00003","title":"Embryonic Stem Cell Transplantation","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Pluripotent Stem Cells Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University","funders":"","keywords":"Transplantation; Stem cell; Medicine; Myocyte; Progenitor cell; Embryonic stem cell; Cell therapy; Angiogenesis; Stem-cell therapy; Internal medicine; Pathology; Biology; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.03194788123583159,"gpt":0.2997860719150581,"spread":0.2678381906792265,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001091166,0.0003727631,0.0006051514,0.0001204557,0.00008943023,0.00002535173,0.0004592787,0.00052747,0.00002275084],"category_scores_gemma":[0.000003014649,0.0003214734,0.0004958496,0.0001663261,0.00006951147,0.000002146657,0.00008586983,0.0002312346,0.0006249226],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004202501,"about_ca_system_score_gemma":0.0004280009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006070776,"about_ca_topic_score_gemma":0.000002806738,"domain_scores_codex":[0.9982036,0.0001956418,0.0003366263,0.0006032095,0.0002691851,0.0003916861],"domain_scores_gemma":[0.9990998,0.00002184629,0.0001634633,0.0005396533,0.00004770874,0.0001275631],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002069451,0.00008469851,0.000002531307,0.01590432,0.0001316031,0.00008898076,0.00002944273,9.519278e-7,0.001541568,0.00000443381,0.01743768,0.9647531],"study_design_scores_gemma":[0.0001883275,0.00007487195,0.000001500705,0.0006737036,0.0001017351,0.0001899943,0.000004863005,6.187983e-7,0.002275086,3.45279e-7,0.9961485,0.0003404403],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001351922,0.9950069,0.00005930835,0.000008678867,0.0001961001,0.0005606822,0.0001789936,0.00002109971,0.003833113],"genre_scores_gemma":[0.00003684811,0.9834715,0.0000577563,0.00001952517,0.0002633824,0.00007929342,0.001504698,0.00006868348,0.01449831],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9787108,"threshold_uncertainty_score":0.9999237,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2954341438","doi":"10.1007/s40259-019-00361-6","title":"Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Ankylosing spondylitis; Tolerability; Interleukin 17; Immunology; Disease; Interleukin 23; Interleukin 22; Clinical trial; Psoriasis Area and Severity Index; Spondylitis; Interleukin; Dermatology; Internal medicine; Cytokine; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.04080093537706545,"gpt":0.2807410066708714,"spread":0.239940071293806,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002107591,0.0004510217,0.001253092,0.0001182247,0.0002058132,0.00002245598,0.0001805655,0.0002765025,0.00005371866],"category_scores_gemma":[0.0000498751,0.0002216179,0.0004928327,0.0001249668,0.0003937945,0.00003906135,0.0000767556,0.00008088016,0.00001803585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006969886,"about_ca_system_score_gemma":0.0001446353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008755975,"about_ca_topic_score_gemma":0.00002592907,"domain_scores_codex":[0.9984419,0.0002144344,0.0006151392,0.0004064819,0.00004579782,0.000276218],"domain_scores_gemma":[0.9973834,0.001510275,0.0005021715,0.0005261723,0.00004611121,0.00003194219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000378549,0.0002301894,0.00009496553,0.004344025,0.002001854,0.000003214579,0.000843376,4.432663e-8,0.00002975906,0.0002230397,0.0005401447,0.9913108],"study_design_scores_gemma":[0.001691293,0.000655104,0.0002430112,0.002033919,0.006708418,0.00003623845,0.0001241937,0.000001035936,0.000238847,0.00002710742,0.9880186,0.0002222561],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01443989,0.9755358,0.000002884281,0.0001253839,0.0009947588,0.001945595,0.006924829,0.00001438112,0.00001645456],"genre_scores_gemma":[0.003976788,0.9940702,0.00002312804,0.00001334237,0.0001561245,0.0003091307,0.0006131505,0.00003559155,0.0008024979],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9910886,"threshold_uncertainty_score":0.9037316,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1976055108","doi":"10.2165/00063030-200317040-00006","title":"Meta-Analysis of Basiliximab for Immunoprophylaxis in Renal Transplantation","year":2003,"lang":"en","type":"review","venue":"BioDrugs","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Simon Fraser University; University of British Columbia","funders":"","keywords":"Basiliximab; Medicine; Transplantation; Internal medicine; Azathioprine; Placebo; Kidney transplantation; Gastroenterology; Surgery; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1943935681286605,"gpt":0.3986355242844454,"spread":0.2042419561557849,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002457548,0.0003515313,0.004268648,0.00097577,0.00002170159,0.000008510068,0.00008848826,0.0002127806,0.0002480352],"category_scores_gemma":[0.000007803534,0.0002262847,0.004541533,0.001141682,0.00003163689,0.00003581728,0.000002550189,0.0001167905,0.00001014038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007427835,"about_ca_system_score_gemma":0.0001512974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007351897,"about_ca_topic_score_gemma":0.00002402386,"domain_scores_codex":[0.9980447,0.0001113179,0.001016982,0.0003744957,0.0002622443,0.0001903191],"domain_scores_gemma":[0.9989203,0.0002448538,0.0003719299,0.000329277,0.00007504765,0.00005856281],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.0003167207,0.0006727744,0.00009565648,0.07682578,0.7099204,0.0001106505,0.0003013784,0.000008480794,0.000008974102,0.0003076484,0.00001554694,0.211416],"study_design_scores_gemma":[0.001382851,0.0001674196,0.0001161883,0.001077947,0.8668836,0.00002719939,0.000006153107,0.000004173455,0.00004382653,0.000008919278,0.1300898,0.0001919123],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002106202,0.9962701,0.0003186879,0.00001186535,0.00005880434,0.001389662,0.001532384,0.00001064137,0.0003868359],"genre_scores_gemma":[0.000109489,0.9930032,0.002084641,0.00002755169,0.000009533963,0.0003498932,0.003083918,0.00003018039,0.001301627],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2112241,"threshold_uncertainty_score":0.9227623,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2061784015","doi":"10.2165/11539070-000000000-00000","title":"Systemic and Mucosal Delivery of Drugs within Polymeric Microparticles Produced by Spray Drying","year":2010,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Spray drying; Drug delivery; Controlled release; Drug; Dosage form; Chitosan; Pharmacology; Nanotechnology; Materials science; Chemistry; Medicine; Chromatography; Organic chemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.02081753502042624,"gpt":0.2911116718339339,"spread":0.2702941368135077,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004162976,0.0004201168,0.001536514,0.0002717428,0.00008882487,0.00002861874,0.0001420638,0.0004287974,0.00003444175],"category_scores_gemma":[0.00006479475,0.0003072183,0.0002821794,0.0003184685,0.0002307607,0.00006789818,0.00007926127,0.0005273327,0.00008152213],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005890409,"about_ca_system_score_gemma":0.0005091539,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002756915,"about_ca_topic_score_gemma":6.975988e-7,"domain_scores_codex":[0.9977698,0.000168704,0.000947732,0.0005178672,0.0003125547,0.0002833153],"domain_scores_gemma":[0.9984142,0.00009706443,0.0006722134,0.0004840721,0.0001357643,0.0001967133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005838335,0.0001772386,0.0001127956,0.04080615,0.0002776379,0.00003222574,0.0007550324,3.931205e-8,0.1722217,0.00003037026,0.001909739,0.7836187],"study_design_scores_gemma":[0.001218919,0.0001508084,0.000004305406,0.02155138,0.002261881,0.000549325,0.0003712869,0.00000808009,0.07227436,5.062245e-7,0.9008448,0.0007643551],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.138836,0.8595902,7.127007e-7,0.00003792626,0.0004348717,0.0008437033,0.0000615193,0.00006456337,0.0001304556],"genre_scores_gemma":[0.02561319,0.9729504,0.0001200592,0.0001381265,0.0002969086,0.0000393893,0.00007559702,0.00008218139,0.0006841536],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8989351,"threshold_uncertainty_score":0.999938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2613074462","doi":"10.1007/s40259-017-0219-4","title":"Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents","year":2017,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Concordance; Immunoassay; Cross-reactivity; Infliximab; Antibody; Rheumatoid arthritis; Internal medicine; Cross reactions; Immunology; Tumor necrosis factor alpha","retraction":null,"screen_n_in":null,"score":{"opus":0.09935088227926661,"gpt":0.395455338091884,"spread":0.2961044558126174,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002148638,0.0001668833,0.0004513293,0.0001099852,0.000362895,0.00004230562,0.0003988792,0.00009680399,0.00004599263],"category_scores_gemma":[0.0005041592,0.0001002234,0.00008756528,0.0002154945,0.0008697678,0.0001887078,0.0002197177,0.0001715402,0.000001075848],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003403135,"about_ca_system_score_gemma":0.0001014105,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009983102,"about_ca_topic_score_gemma":0.0001219614,"domain_scores_codex":[0.9983992,0.0005424585,0.0002972811,0.0003793853,0.0001710843,0.0002105802],"domain_scores_gemma":[0.9981078,0.00005668439,0.0004838015,0.0009318094,0.0003944441,0.000025463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0001132694,0.0001321655,0.2865266,0.00001889988,0.0005997904,2.779624e-7,0.0002406645,0.00002393014,0.7062696,0.00003489307,0.00001684447,0.006023066],"study_design_scores_gemma":[0.0004680688,0.00005410368,0.6140878,0.00003615311,0.001006876,0.000004455067,0.00006823883,0.0002433786,0.3837739,0.00003292489,0.0001243732,0.0000997991],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984454,0.0005216785,0.00004309891,0.0001632188,0.000107552,0.0003124876,0.00009989426,0.000008485511,0.0002981922],"genre_scores_gemma":[0.9988784,0.00003318155,0.0009355702,0.00003003953,0.00001041725,0.000003490185,0.000009248256,0.000007149959,0.00009246375],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3275612,"threshold_uncertainty_score":0.4086994,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2930500067","doi":"10.1007/s40259-019-00346-5","title":"Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting","year":2019,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Stockholms Läns Landsting","keywords":"Biosimilar; Market share; Medical prescription; Etanercept; Pharmacy; Prior authorization; Business; Reimbursement; Medicine; Quarter (Canadian coin); Marketing; Family medicine; Public economics; Health care; Economics; Economic growth; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.01744734384482944,"gpt":0.298849918284737,"spread":0.2814025744399076,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001063837,0.000222979,0.0003317301,0.000106024,0.000132173,0.00008473379,0.0002222924,0.0002359316,0.00008463009],"category_scores_gemma":[0.0004897172,0.0001348858,0.00004414735,0.0001455903,0.0003611883,0.0001366172,0.0001319769,0.0004029431,0.00001293913],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005276714,"about_ca_system_score_gemma":0.00004023566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002030554,"about_ca_topic_score_gemma":0.00009533692,"domain_scores_codex":[0.9982861,0.0005907639,0.0003077991,0.0003675954,0.00008986209,0.0003579302],"domain_scores_gemma":[0.9986047,0.0008096507,0.0002439151,0.0002566737,0.00005121354,0.0000338464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001119603,0.00008851798,0.9771655,0.0001153938,0.0001375376,0.000003106663,0.001151105,1.518109e-7,0.002373799,0.001311793,0.002924246,0.01461686],"study_design_scores_gemma":[0.001002374,0.0003174203,0.8381563,0.0001349408,0.000140298,0.00002958966,0.002927042,0.00004820752,0.001691455,0.000601568,0.1545541,0.0003966485],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884807,0.00227787,0.000004670417,0.007430138,0.0001920709,0.0003570336,0.0001270154,0.00002359794,0.001106827],"genre_scores_gemma":[0.9974528,0.0005818427,0.00009741397,0.001194335,0.00005857298,0.0000134378,0.00001897494,0.00000986662,0.0005727814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1516299,"threshold_uncertainty_score":0.5500482,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388902238","doi":"10.1007/s40259-023-00630-5","title":"Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Celltrion","keywords":"Ustekinumab; Medicine; Psoriasis Area and Severity Index; Clinical endpoint; Biosimilar; Dosing; Adverse effect; Randomized controlled trial; Psoriasis; Tolerability; Internal medicine; Dermatology; Adalimumab","retraction":null,"screen_n_in":null,"score":{"opus":0.04463726408912411,"gpt":0.3397974502253265,"spread":0.2951601861362024,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001661106,0.0003926819,0.001473856,0.0005322935,0.0001293915,0.00001991681,0.0003186022,0.0002665096,0.00007587575],"category_scores_gemma":[0.0003729264,0.0003031415,0.0001913711,0.0009531698,0.0002445491,0.000096257,0.0002002303,0.0003592908,0.00002597159],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007088396,"about_ca_system_score_gemma":0.0001617998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005211662,"about_ca_topic_score_gemma":0.0002453225,"domain_scores_codex":[0.9967947,0.0006460561,0.001177886,0.0006997507,0.0001251358,0.0005564691],"domain_scores_gemma":[0.9977064,0.001177675,0.0003682094,0.0004917154,0.0001506869,0.0001053107],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9708815,0.001703028,0.00006996475,0.00004289368,0.001219016,0.00004067534,0.001678055,0.00003610981,0.01743956,0.00008598217,0.001262679,0.00554055],"study_design_scores_gemma":[0.9095122,0.00222271,0.0004390168,0.0001039162,0.0004383072,0.000008593705,0.001755833,0.00008279959,0.08051165,0.00002285006,0.00452345,0.000378702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993409,0.0004862133,0.00002114077,0.0007897529,0.0006749753,0.003450375,0.000701561,0.0000578387,0.0004091708],"genre_scores_gemma":[0.9986297,0.0003059056,0.0001420115,0.00006628539,0.00003286802,0.0001392816,0.00007320533,0.00002464028,0.0005861078],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06307209,"threshold_uncertainty_score":0.9999421,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2905052297","doi":"10.1007/s40259-018-0325-y","title":"Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies","year":2018,"lang":"en","type":"review","venue":"BioDrugs","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Hereditary angioedema; Medicine; C1-inhibitor; Dosing; Tolerability; Kallikrein; Pharmacokinetics; Angioedema; Pharmacology; Pharmacodynamics; Internal medicine; Immunology; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.1589567030262765,"gpt":0.4415890634976389,"spread":0.2826323604713624,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004376372,0.000409701,0.002491246,0.00009155482,0.00009192936,0.000006703226,0.0001142888,0.0001506178,0.00002015225],"category_scores_gemma":[0.0003369461,0.0001921327,0.0006016797,0.0002834164,0.0005576664,0.00004040021,0.00003835432,0.00006991512,0.000003066012],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008193368,"about_ca_system_score_gemma":0.0006644189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004072921,"about_ca_topic_score_gemma":0.00001562739,"domain_scores_codex":[0.9978836,0.00009009624,0.001052408,0.000438187,0.0003009949,0.0002347759],"domain_scores_gemma":[0.9972484,0.0009762161,0.0008097246,0.0005366563,0.0003300399,0.00009899136],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002289512,0.0007213156,0.00003589756,0.2087159,0.001015144,0.000009188551,0.0003795547,1.04517e-8,3.640147e-7,0.00003822236,0.004219957,0.7846355],"study_design_scores_gemma":[0.002637054,0.007159389,0.00002441527,0.1105276,0.0112391,0.0001463205,0.0001549372,0.000005783473,0.00002583895,0.00001736518,0.8678162,0.0002459931],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000236289,0.9948738,0.000009336252,0.0004025129,0.0002192573,0.003992637,0.0002041516,0.00002127868,0.00004071775],"genre_scores_gemma":[0.0004038656,0.9975681,0.0004538056,0.00007133457,0.0006003951,0.0003757664,0.0001105547,0.00004145153,0.0003747498],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8635962,"threshold_uncertainty_score":0.7834945,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310776690","doi":"10.1007/s40259-022-00568-0","title":"The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries","year":2022,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Biosimilar; China; Medicine; Biopharmaceutical; European union; Business; Product (mathematics); International trade; Biotechnology; Geography","retraction":null,"screen_n_in":null,"score":{"opus":0.02814807893878446,"gpt":0.2996754926621776,"spread":0.2715274137233932,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007823741,0.0001502368,0.0003844328,0.00004533769,0.000174686,0.000005230463,0.000307375,0.0001557772,0.0005179698],"category_scores_gemma":[0.00008448018,0.00009005982,0.0001233738,0.0001619761,0.0006261227,0.00002191771,0.0002019718,0.0001433439,0.000001805644],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001803022,"about_ca_system_score_gemma":0.00004082914,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004695346,"about_ca_topic_score_gemma":0.00001593883,"domain_scores_codex":[0.9986393,0.0004950762,0.0003513416,0.0002313824,0.00007124274,0.0002116311],"domain_scores_gemma":[0.9989986,0.0003663089,0.0002556318,0.000298314,0.00005856195,0.00002261427],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03236121,0.003649337,0.3295813,0.002025615,0.007392715,0.0000404014,0.003177611,0.00002351657,0.2710113,0.1281553,0.1227921,0.09978949],"study_design_scores_gemma":[0.004707746,0.004751787,0.1741641,0.0001287311,0.0005778999,0.00005828409,0.004804013,0.00003042763,0.4014044,0.006609918,0.4021051,0.0006575485],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.955738,0.0389355,0.000005541793,0.001488997,0.0004819962,0.0002817951,0.00204734,0.00001712591,0.001003669],"genre_scores_gemma":[0.9969292,0.00203758,0.0002085867,0.000540913,0.000009607562,0.000008297285,0.0000346156,0.000005657706,0.0002255724],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2793129,"threshold_uncertainty_score":0.5671406,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2024217378","doi":"10.2165/00063030-200014020-00006","title":"Photodynamic Therapy in Immune (Non-Oncological) Disorders","year":2000,"lang":"en","type":"article","venue":"BioDrugs","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; QLT (Canada)","funders":"","keywords":"Photodynamic therapy; Verteporfin; Medicine; Immune system; Cancer research; Immunology; Chemistry; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.01153634557335672,"gpt":0.3003189062959898,"spread":0.2887825607226331,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002927816,0.0002039391,0.0004081769,0.0001480832,0.00007909493,0.00001380577,0.0001865527,0.0001091336,0.002425924],"category_scores_gemma":[0.00003391671,0.0001499002,0.0001388631,0.0004307175,0.0002265049,0.00005804647,0.00003471798,0.0003052086,0.0002561659],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001894644,"about_ca_system_score_gemma":0.00009854324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000566772,"about_ca_topic_score_gemma":0.0001420999,"domain_scores_codex":[0.9985324,0.00006673396,0.0002892744,0.000333788,0.0002817494,0.0004960732],"domain_scores_gemma":[0.9993848,0.00009152306,0.00003365684,0.0003591046,0.00002572632,0.0001051425],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.003023531,0.001471934,0.01007636,0.00004570671,0.0002032059,0.0001121345,0.001837673,0.0000127565,0.3583437,0.00002546703,0.0009054766,0.6239421],"study_design_scores_gemma":[0.01215973,0.00232648,0.8778387,0.0001491033,0.00001715619,0.00003041705,0.0006116634,0.0009124284,0.01151793,0.0008251075,0.09309099,0.0005202982],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9750637,0.001988181,0.000001811573,0.001937204,0.00006337225,0.0009057527,0.000008896205,0.00009154459,0.01993953],"genre_scores_gemma":[0.978471,0.01588462,0.00008462708,0.0005449488,0.00004566467,0.0001504847,0.00002004791,0.00002392751,0.004774654],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8677623,"threshold_uncertainty_score":0.998486,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W204758488","doi":"10.2165/00063030-200721010-00002","title":"Therapeutic and Prophylactic Potential of Small Interfering RNAs against Severe Acute Respiratory Syndrome","year":2007,"lang":"en","type":"review","venue":"BioDrugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Small interfering RNA; RNA interference; Virology; RNA; Biology; Medicine; Coronavirus; Immunology; Coronavirus disease 2019 (COVID-19); Gene; Infectious disease (medical specialty); Pathology; Disease","retraction":null,"screen_n_in":null,"score":{"opus":0.0431896343897843,"gpt":0.3051160456634367,"spread":0.2619264112736524,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002095246,0.0004105119,0.0007826927,0.0001641685,0.00004827858,0.00003395229,0.0003583998,0.0005013557,0.00001010192],"category_scores_gemma":[0.00001236612,0.0003405006,0.0003544876,0.000112377,0.000134256,0.000004639727,0.000261546,0.0002420844,0.00002087093],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002555372,"about_ca_system_score_gemma":0.0001924802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007259073,"about_ca_topic_score_gemma":0.000004529524,"domain_scores_codex":[0.9984059,0.00009605077,0.0005363322,0.0005352851,0.0001251378,0.0003012346],"domain_scores_gemma":[0.998999,0.00001286003,0.0003277876,0.0004843254,0.00008328923,0.00009272822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006540406,0.00005157064,0.000008315864,0.003994962,0.0007263802,0.0000985744,0.00002212861,6.379178e-7,0.01480247,0.000004015539,0.00009122986,0.9801343],"study_design_scores_gemma":[0.0003876002,0.001067367,0.00004631224,0.002990234,0.0009188935,0.0006082883,0.00003818245,0.000002333706,0.004640493,0.000007403347,0.988503,0.0007898368],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03489539,0.9638144,0.0001524118,0.000003710197,0.000302789,0.0003992452,0.0000885413,0.00001228624,0.0003312588],"genre_scores_gemma":[0.02075198,0.9780937,0.00009852349,0.000132168,0.0001685499,0.00002160378,0.0001259411,0.00005715385,0.0005503492],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9884118,"threshold_uncertainty_score":0.9999047,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2961547340","doi":"10.1007/s40259-019-00366-1","title":"Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Inflammatory bowel disease; Ulcerative colitis; Drug; Therapeutic drug monitoring; Personalized medicine; Monoclonal antibody; Pharmacodynamics; Dosing; Pharmacokinetics; Crohn's disease; Precision medicine; Efficacy; Disease; Pharmacotherapy; Pharmacology; Immunology; Intensive care medicine; Internal medicine; Bioinformatics; Antibody; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1079329269223195,"gpt":0.4040673753673309,"spread":0.2961344484450115,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004202461,0.0005874191,0.002160318,0.0007497297,0.0001092596,0.00001795198,0.000331283,0.0002389602,0.0001119246],"category_scores_gemma":[0.0002452891,0.0003944931,0.0008786236,0.0003737327,0.0004560317,0.0001091945,0.0001298487,0.0004298433,0.00002355064],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002545218,"about_ca_system_score_gemma":0.0009282863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001809521,"about_ca_topic_score_gemma":0.00001286093,"domain_scores_codex":[0.9970186,0.0001353748,0.001198592,0.000626217,0.0005042371,0.0005170084],"domain_scores_gemma":[0.9975162,0.0008334724,0.000513127,0.000537338,0.0002660011,0.0003339286],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001688259,0.0008695516,0.2328351,0.4161422,0.002021845,0.00004679777,0.003577172,0.00000396736,0.0005585685,0.02214891,0.011654,0.3084537],"study_design_scores_gemma":[0.001256999,0.0001458737,0.09032697,0.03072762,0.001334858,0.00001268809,0.0002006057,0.00002065424,0.00001361053,0.0002280963,0.8752213,0.0005107597],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0235865,0.9709499,0.00001114454,0.0009044142,0.0001791433,0.002719139,0.001339989,0.00003919463,0.000270593],"genre_scores_gemma":[0.00162377,0.9912589,0.000116475,0.00007269082,0.0003441962,0.0002995571,0.002967654,0.00007607327,0.003240723],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8635672,"threshold_uncertainty_score":0.9998507,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2073194177","doi":"10.2165/00063030-200620010-00001","title":"The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases","year":2006,"lang":"en","type":"review","venue":"BioDrugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"NOSM University; University of Alberta","funders":"National Heart, Lung, and Blood Institute","keywords":"Oligonucleotide; Genetic enhancement; Small interfering RNA; RNA interference; RNA; Immune system; Biology; Translation (biology); Medicine; Pharmacology; Messenger RNA; Computational biology; Gene; Immunology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02334919196402986,"gpt":0.3058975377542738,"spread":0.282548345790244,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009717399,0.000215293,0.0004682045,0.00004447118,0.00004123974,0.00001238328,0.0003365985,0.0001606799,0.000002204881],"category_scores_gemma":[0.000009114109,0.0001017139,0.0004315319,0.0001075762,0.0001461357,0.000001146729,0.00002947231,0.00004608118,0.000004016055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001284419,"about_ca_system_score_gemma":0.0001351112,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003755507,"about_ca_topic_score_gemma":0.00008726559,"domain_scores_codex":[0.9989493,0.0001862002,0.0004013486,0.0002138901,0.0001034224,0.0001457644],"domain_scores_gemma":[0.9990687,0.00004971989,0.0002542785,0.0005659799,0.0000424782,0.00001885363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002968515,0.000240501,0.0001526013,0.0008306172,0.0001279506,0.000008181252,0.00004299644,4.882997e-7,0.000345581,0.00004286038,0.007268562,0.99091],"study_design_scores_gemma":[0.0001156461,0.0003790816,0.0001947554,0.000360533,0.000162783,0.000003125256,0.00008685871,8.489607e-8,0.001060337,0.000006424188,0.9975253,0.000105016],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01742215,0.9816609,3.304024e-7,0.00001672161,0.0001514608,0.0003209204,0.0002295571,0.000001889108,0.0001960847],"genre_scores_gemma":[0.002518828,0.9967026,0.000005160671,0.00002563318,0.000401596,0.00003980805,0.0001316128,0.0000138005,0.0001609547],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.990805,"threshold_uncertainty_score":0.4147773,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1990941062","doi":"10.2165/00063030-200822040-00005","title":"Anti-Adhesion Molecule Strategies for Crohn Disease","year":2008,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Infliximab; Crohn's disease; Adalimumab; Medicine; Monoclonal antibody; Disease; Tumor necrosis factor alpha; Monoclonal antibody therapy; Inflammatory bowel disease; Immunology; Monoclonal; Certolizumab pegol; Antibody; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02500131258589668,"gpt":0.3008105274606349,"spread":0.2758092148747383,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00007782197,0.0005430697,0.0006743632,0.00009292139,0.0001652481,0.00007208381,0.0004292769,0.0003961135,0.0000207104],"category_scores_gemma":[0.00008078317,0.0004804119,0.0009471261,0.00008328376,0.0001340511,0.000006272237,0.0001502829,0.0001111724,0.0001079233],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003217967,"about_ca_system_score_gemma":0.001459296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002213512,"about_ca_topic_score_gemma":0.000001475795,"domain_scores_codex":[0.9981248,0.0001073659,0.0004450233,0.0007276082,0.0001742363,0.0004209987],"domain_scores_gemma":[0.998539,0.00001699346,0.0002509001,0.0007902533,0.0001048051,0.0002981013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008575069,0.0009131284,0.00009119441,0.08042689,0.001373254,0.004022689,0.00008684079,0.00001837073,0.001015087,0.001792504,0.3034296,0.6059729],"study_design_scores_gemma":[0.000277968,0.00003317922,0.0002572423,0.0008822642,0.000294595,0.00001512077,0.00001097007,0.000002905451,0.00004205305,0.00002896594,0.9975573,0.0005973867],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009914383,0.9959965,0.0001563009,0.000007636471,0.0002852363,0.001320419,0.0007606214,0.00004481895,0.0004369863],"genre_scores_gemma":[0.0002416089,0.9950783,0.0001780398,0.00009512709,0.00063973,0.00041884,0.00243108,0.0001144266,0.0008028579],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6941278,"threshold_uncertainty_score":0.9997647,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3167186946","doi":"10.1007/s40259-021-00486-7","title":"Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy","year":2021,"lang":"en","type":"review","venue":"BioDrugs","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Women and Children's Health Research Institute","keywords":"Spinal muscular atrophy; Duchenne muscular dystrophy; SMA*; Exon skipping; Medicine; Dystrophin; Neuromuscular disease; Muscular dystrophy; Antisense therapy; Motor neuron; Weakness; Bioinformatics; Genetic enhancement; Exon; Internal medicine; Disease; Biology; Surgery; Genetics; Gene; microRNA; Alternative splicing","retraction":null,"screen_n_in":null,"score":{"opus":0.0616848120403912,"gpt":0.4081047040783568,"spread":0.3464198920379656,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001184622,0.0005458782,0.00194847,0.000334415,0.0003490686,0.00007351861,0.0002401681,0.0001255455,0.000007485318],"category_scores_gemma":[0.0004328106,0.000363907,0.0006728777,0.0005619897,0.0002746766,0.00009951521,0.0007153502,0.0006706914,7.963662e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008527484,"about_ca_system_score_gemma":0.0004852977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001722829,"about_ca_topic_score_gemma":0.000001506785,"domain_scores_codex":[0.9960963,0.0008301272,0.0009732053,0.000890202,0.0007482298,0.0004619257],"domain_scores_gemma":[0.998126,0.000132919,0.0004562276,0.0008547035,0.0002569511,0.0001731593],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000201426,0.0001434924,0.000007849916,0.1020274,0.0001374969,0.00006896705,0.0001083516,4.007669e-7,0.004758536,0.00001047496,0.00002305695,0.8926938],"study_design_scores_gemma":[0.001189961,0.0003471608,0.0003763385,0.1877151,0.001096828,0.0001117563,0.00003608812,0.00001640635,0.0003389174,0.0000734586,0.8083009,0.0003971147],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02886173,0.9653127,0.0002971603,0.000270691,0.0001032459,0.005088511,0.00004143186,0.00002003172,0.000004489388],"genre_scores_gemma":[0.0009105922,0.9962028,0.001280824,0.00005030955,0.0001088435,0.001174946,0.0001596893,0.00009002577,0.00002193959],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8922967,"threshold_uncertainty_score":0.9998813,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2029930411","doi":"10.1007/s40259-014-0099-9","title":"Similar Names for Similar Biologics","year":2014,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Probity Medical Research","funders":"Amicus Therapeutics; Amgen","keywords":"Biosimilar; Pharmacovigilance; Interchangeability; Medicine; Product (mathematics); Pharmacology; Computer science; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.02234148561895411,"gpt":0.2784489941231749,"spread":0.2561075085042208,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007619744,0.0002225573,0.0003623361,0.00006401271,0.0001961683,0.00001958278,0.0002944552,0.0004778827,0.0005089776],"category_scores_gemma":[0.0005686913,0.0001573935,0.0002219403,0.0001200438,0.0003162359,0.00003554694,0.00008096681,0.0001802253,0.0002027195],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001785701,"about_ca_system_score_gemma":0.00002225061,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005714773,"about_ca_topic_score_gemma":0.000003002012,"domain_scores_codex":[0.9985956,0.0002121234,0.0002825201,0.0004071515,0.00002626564,0.0004763438],"domain_scores_gemma":[0.9988815,0.0005581626,0.0000896803,0.0003426247,0.00008589441,0.0000421546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005442615,0.0004856995,0.005032485,0.000142733,0.0005624224,0.000002446182,0.0002005742,0.00000516821,0.4732326,0.05878359,0.290741,0.170267],"study_design_scores_gemma":[0.0008044739,0.0003701028,0.0008027279,0.00001234611,0.00006646314,0.000006430365,0.00005108788,0.00009696518,0.1015587,0.006055009,0.8899129,0.0002627886],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4015887,0.04277906,0.2887388,0.1248036,0.02718434,0.007881857,0.003430509,0.003888769,0.09970435],"genre_scores_gemma":[0.9499135,0.00023024,0.02978426,0.009940424,0.0003682075,0.00007618874,0.0001721767,0.00004570197,0.009469297],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5991719,"threshold_uncertainty_score":0.641832,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4404773045","doi":"10.1007/s40259-024-00687-w","title":"Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa","year":2024,"lang":"en","type":"review","venue":"BioDrugs","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Saskatchewan","funders":"Fundação para a Ciência e a Tecnologia; Universidade do Porto","keywords":"Medicine; Secukinumab; Hidradenitis suppurativa; Clinical trial; Dermatology; Quality of life (healthcare); Psoriasis; Pharmacology; Intensive care medicine; Disease; Internal medicine; Psoriatic arthritis","retraction":null,"screen_n_in":null,"score":{"opus":0.06812192845542084,"gpt":0.3786615047880245,"spread":0.3105395763326037,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000009307686,0.0006800777,0.002114613,0.000524988,0.00004183256,0.00005144312,0.0002221823,0.0003361622,0.0002061997],"category_scores_gemma":[0.00002087919,0.0003327032,0.001052524,0.0007473542,0.0001617754,0.0000650905,0.00003352495,0.0003205478,0.0005375066],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005148656,"about_ca_system_score_gemma":0.000416802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001388513,"about_ca_topic_score_gemma":0.00004966277,"domain_scores_codex":[0.9975382,0.0002335815,0.0009579995,0.0005245709,0.0003920143,0.0003536454],"domain_scores_gemma":[0.9987819,0.0002235055,0.000217397,0.0006413065,0.00003321314,0.0001026718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002099539,0.001140075,0.00004839293,0.007072126,0.0006649502,0.04905687,0.004545923,1.002459e-9,0.000001372805,0.0001098164,0.00642093,0.9309186],"study_design_scores_gemma":[0.0007192045,0.00113045,0.00000408548,0.01514111,0.003123852,0.03506536,0.0003322107,4.091344e-7,0.00002282601,0.00002428355,0.9442005,0.0002357556],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001028433,0.9901857,2.414554e-7,0.002161691,0.0004700253,0.002135657,0.0003206512,0.00004917244,0.004573988],"genre_scores_gemma":[0.01215644,0.9809167,0.00003939161,0.000003959074,0.0004045486,0.0004697915,0.0006320403,0.00007332556,0.005303803],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9377795,"threshold_uncertainty_score":0.9999125,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2030438860","doi":"10.2165/11206830-000000000-00000","title":"Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)†","year":2011,"lang":"en","type":"article","venue":"BioDrugs","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Immunogenicity; Medicine; Cervical cancer; Virology; Adjuvant; Immunology; Cervical intraepithelial neoplasia; HPV vaccines; DNA vaccination; Immune system; Vaccination; HPV infection; Immunization; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.08524794751241882,"gpt":0.3382199901668697,"spread":0.2529720426544509,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001803717,0.0001805744,0.0003230951,0.0001482744,0.0001252995,0.00002119527,0.0001189865,0.0001195909,0.02867454],"category_scores_gemma":[0.00003846074,0.0001340087,0.00007449667,0.0002069953,0.00007378358,0.00005163529,0.00009108372,0.0002632404,0.0005471694],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000797147,"about_ca_system_score_gemma":0.00004686261,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007697138,"about_ca_topic_score_gemma":0.0001325892,"domain_scores_codex":[0.9987242,0.00003614174,0.0002184989,0.0003564324,0.0003158727,0.0003489107],"domain_scores_gemma":[0.9991372,0.00003743199,0.00004051534,0.0003737741,0.00011701,0.0002940385],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01205473,0.002644432,0.1015455,0.001176769,0.0007333141,0.00076282,0.003106782,1.105589e-7,0.02416643,0.02696728,0.140341,0.6865008],"study_design_scores_gemma":[0.004289041,0.001457926,0.8746372,0.00005322577,0.0001033149,0.00003100541,0.000119557,0.00001242945,0.02853668,0.001256176,0.08922437,0.0002790748],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5450166,0.00183952,0.000008848354,0.001227278,0.0001715415,0.0004444944,0.00002720332,0.0001749367,0.4510896],"genre_scores_gemma":[0.9916438,0.0002917861,0.00009114423,0.001312062,0.0002930737,0.00001584672,0.00003111029,0.00003499727,0.006286157],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7730917,"threshold_uncertainty_score":0.9722134,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012092068","doi":"10.2165/00063030-200317001-00006","title":"Current Status and Replies to Frequently Posed Questions on Atovaquone Plus Proguanil (Malarone??) for the Prevention of Malaria","year":2003,"lang":"en","type":"review","venue":"BioDrugs","topic":"Malaria Research and Control","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Proguanil; Malaria; Atovaquone; Mefloquine; Medicine; Chloroquine; Chemoprophylaxis; Malaria prophylaxis; Artemisinin; Intensive care medicine; Primaquine; Plasmodium falciparum; Pharmacology; Immunology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.07494769191811303,"gpt":0.3959982805013508,"spread":0.3210505885832378,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007474758,0.0003489601,0.001191745,0.0002454722,0.0001287014,0.00004755938,0.0001649523,0.0001921536,0.00007452433],"category_scores_gemma":[0.0006586211,0.0002145027,0.0004084739,0.0002982916,0.0000965957,0.00003663514,0.00006134489,0.0004002332,0.00003013689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002195449,"about_ca_system_score_gemma":0.001156171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000574386,"about_ca_topic_score_gemma":0.00002111009,"domain_scores_codex":[0.997731,0.0002175619,0.0006321962,0.0004993082,0.0004368552,0.0004830332],"domain_scores_gemma":[0.9981654,0.0003308902,0.0002921193,0.0006983045,0.0002283427,0.0002850017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003718142,0.0002752666,0.000008306384,0.01426671,0.0004624374,0.00000356382,0.0000778109,3.392268e-7,0.00002129332,0.01968529,0.00240446,0.9624227],"study_design_scores_gemma":[0.001583421,0.001031648,0.0001941464,0.008925906,0.001358441,0.00001625448,0.0000316953,0.00001184686,0.00001255136,0.000163248,0.9864752,0.0001956754],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003715901,0.9890766,0.0004517768,0.001024758,0.0002719974,0.008521314,0.0003095872,0.00003386411,0.0002729133],"genre_scores_gemma":[0.0002862732,0.9945404,0.0006818105,0.00006346258,0.0002114245,0.001794773,0.0002368631,0.0000485736,0.002136404],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9840707,"threshold_uncertainty_score":0.8747167,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389486878","doi":"10.1007/s40259-023-00636-z","title":"Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Research Foundation of Korea","keywords":"Biosimilar; Adalimumab; Medicine; Significant difference; Intensive care medicine; Internal medicine; Rheumatoid arthritis","retraction":null,"screen_n_in":null,"score":{"opus":0.02774255390288685,"gpt":0.2830068196293937,"spread":0.2552642657265068,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058391,0.0002181741,0.0007942551,0.0003230296,0.00009309051,0.00001176614,0.0004147982,0.0003165959,0.0005671155],"category_scores_gemma":[0.0004742444,0.0001234458,0.0002401112,0.002463083,0.001092929,0.00002436343,0.000128606,0.0002518524,0.00001601618],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000041911,"about_ca_system_score_gemma":0.00008745382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002418975,"about_ca_topic_score_gemma":0.000440097,"domain_scores_codex":[0.9980983,0.0004393543,0.0005607676,0.0003856901,0.0001287622,0.0003871974],"domain_scores_gemma":[0.9977171,0.001192711,0.0003170219,0.0005327266,0.0002162161,0.000024236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004911675,0.0004337815,0.9187063,0.0000914839,0.003907392,0.000004220047,0.002186669,0.000003822531,0.06920481,0.0006245242,0.002537531,0.00180828],"study_design_scores_gemma":[0.0007021631,0.0002089921,0.9341252,0.00008383821,0.0009937539,6.692184e-7,0.0003968065,0.0001505437,0.06206214,0.0002494786,0.0008453389,0.0001810579],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995486,0.0006208299,0.00003523625,0.002315116,0.0001022949,0.0002117235,0.0009764222,0.00004547678,0.0002068714],"genre_scores_gemma":[0.9979181,0.0001938527,0.00005503701,0.0003884519,0.000004478104,0.00001209477,0.00006845719,0.000008501201,0.001351076],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0154189,"threshold_uncertainty_score":0.6209517,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W217783584","doi":"10.1007/s40259-015-0126-5","title":"Status and Prospects of Aptamers as Drug Components","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Advanced biosensing and bioanalysis techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Carleton University","funders":"","keywords":"Aptamer; Drug; Pharmacotherapy; Medicine; Computational biology; Intensive care medicine; Pharmacology; Biology; Internal medicine; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02908022629780935,"gpt":0.335241854693982,"spread":0.3061616283961726,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001898208,0.0003337111,0.0009151549,0.0001059254,0.00003462818,0.00001580114,0.0001593627,0.0002687942,0.000001068267],"category_scores_gemma":[0.00004893196,0.0002549313,0.000245977,0.0001554288,0.0002221575,0.000002082127,0.0001899942,0.0001231095,0.000005888748],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002870827,"about_ca_system_score_gemma":0.0001721353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003426998,"about_ca_topic_score_gemma":0.000006088159,"domain_scores_codex":[0.9986229,0.00008669402,0.0003813056,0.0004754783,0.000182277,0.0002513239],"domain_scores_gemma":[0.9989325,0.00000998758,0.0003738662,0.0004232987,0.0001168838,0.0001434993],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003328763,0.0001084641,0.00005311048,0.003432495,0.0004272379,0.000006743154,0.00003577892,2.166279e-8,0.003624853,0.00005089874,0.003745406,0.9884817],"study_design_scores_gemma":[0.000127842,0.0001012497,0.000002703547,0.0009187874,0.000312377,0.00001770334,0.00002351304,3.181372e-7,0.005485912,0.00003748559,0.992673,0.0002991507],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002108642,0.996664,0.000003695556,0.000008391594,0.00006458037,0.0003516425,0.0001142937,0.00002742591,0.0006573072],"genre_scores_gemma":[0.003102415,0.9940523,0.001131646,0.00002479058,0.00009571042,0.00001154835,0.0006213388,0.00003558079,0.000924677],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9889275,"threshold_uncertainty_score":0.9999903,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4360601016","doi":"10.1007/s40259-023-00589-3","title":"Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Health and Medical Research Fund; Medical Research Council; University of Hong Kong; National Institute for Health and Care Research; Australian Government; National Health and Medical Research Council; European Commission; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Biosimilar; Infliximab; Medicine; Interrupted time series; Interrupted Time Series Analysis; Consumption (sociology); Demography; Internal medicine; Tumor necrosis factor alpha","retraction":null,"screen_n_in":null,"score":{"opus":0.02306556960911271,"gpt":0.3292944411009679,"spread":0.3062288714918552,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007631847,0.0003661293,0.0008152126,0.001379391,0.0001202531,0.00004930906,0.0002478213,0.0004454672,0.000497718],"category_scores_gemma":[0.0003135783,0.0002836912,0.0002738012,0.001875503,0.0005981078,0.0003276537,0.00016757,0.0003727716,0.0001095078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001225996,"about_ca_system_score_gemma":0.00007527038,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000151832,"about_ca_topic_score_gemma":0.00004966936,"domain_scores_codex":[0.997708,0.0003242657,0.0006715362,0.0006737819,0.00009907549,0.0005233319],"domain_scores_gemma":[0.9986686,0.0003188788,0.0002805582,0.0005397827,0.0001142353,0.00007797431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.005880137,0.001864076,0.4115508,0.000278254,0.006957017,0.00006377898,0.005128696,0.0002729707,0.5338472,0.003214245,0.0076407,0.02330216],"study_design_scores_gemma":[0.005162547,0.002818449,0.8990749,0.0002533766,0.001076536,0.00006067242,0.000616569,0.001678815,0.08223318,0.0005326861,0.005372234,0.001120053],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974874,0.000816495,0.00004020768,0.0006941662,0.0001785104,0.0003072545,0.0001937868,0.0001269895,0.0001551366],"genre_scores_gemma":[0.9975277,0.0004848232,0.001018432,0.0001407549,0.00003952406,0.00002688804,0.0002600632,0.00002602621,0.0004757694],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4875242,"threshold_uncertainty_score":0.9999615,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2009690780","doi":"10.2165/00063030-200418020-00001","title":"Business Ethics 101 for the Biotech Industry","year":2004,"lang":"en","type":"review","venue":"BioDrugs","topic":"Biotechnology and Related Fields","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saint Mary's University","funders":"","keywords":"Drug industry; Business ethics; Business; Management; Biotechnology; Engineering ethics; Medicine; Biology; Engineering; Economics","retraction":null,"screen_n_in":null,"score":{"opus":0.120024753410699,"gpt":0.3866064633007289,"spread":0.2665817098900299,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0004737324,0.0003567002,0.001005851,0.000175969,0.0002543445,0.0000163696,0.0003581404,0.042456,0.00007087997],"category_scores_gemma":[0.0004807324,0.0001848973,0.0004244165,0.0007848548,0.0003919753,0.00001625055,0.00009254411,0.01870924,0.0001442572],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009759984,"about_ca_system_score_gemma":0.001514678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000283736,"about_ca_topic_score_gemma":0.000001722099,"domain_scores_codex":[0.9987059,0.00003877904,0.0004029101,0.0003671946,0.0001691894,0.0003160602],"domain_scores_gemma":[0.998421,0.0004492309,0.0002094194,0.0007135153,0.0001408004,0.00006608995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001555562,0.00007414039,4.348043e-7,0.02679363,0.0005545784,0.00002686754,0.00005195579,1.880703e-7,0.000001181381,0.003898184,0.005435743,0.9631475],"study_design_scores_gemma":[0.0003828443,0.00004787176,0.000003177885,0.02063849,0.002220453,0.0003056006,0.00002729518,8.229423e-7,0.00001948647,0.00008412958,0.9760547,0.0002150787],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[5.228124e-7,0.947875,0.0003757936,0.04881229,0.0009797574,0.00138919,0.00004537918,0.0001799113,0.0003421128],"genre_scores_gemma":[0.000004170287,0.9945615,0.0003558795,0.001015683,0.0004271728,0.0001262662,0.0001006176,0.00005336283,0.003355328],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.970619,"threshold_uncertainty_score":0.9835547,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4407184001","doi":"10.1007/s40259-025-00706-4","title":"TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review","year":2025,"lang":"en","type":"review","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"","keywords":"Inflammatory bowel disease; Medicine; Molecular medicine; Internal medicine; Disease; Pharmacology; Bioinformatics; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01137065343003696,"gpt":0.2901550140829343,"spread":0.2787843606528973,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004765677,0.0006336873,0.0009062626,0.0002497665,0.00005645724,0.00003612573,0.0003100053,0.000441011,0.00007967555],"category_scores_gemma":[0.0004347688,0.0005970838,0.0007521763,0.0002658427,0.00009476818,0.000006775915,0.0003323979,0.0002977505,0.0002151564],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001074629,"about_ca_system_score_gemma":0.001607714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002535381,"about_ca_topic_score_gemma":0.0000134444,"domain_scores_codex":[0.9970511,0.0003991592,0.001025218,0.0008504245,0.0002481621,0.0004259389],"domain_scores_gemma":[0.998171,0.00002585343,0.000364741,0.00107995,0.0001019521,0.0002565444],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001006415,0.0002087193,0.0001459245,0.4863183,0.0001203165,0.001163499,0.000006934783,0.000001613879,0.00001441486,0.0001654277,0.1400152,0.371739],"study_design_scores_gemma":[0.0002718429,0.000008818761,0.000169686,0.09215096,0.0004580363,0.000007646145,0.000001507498,0.000001358636,0.000004416361,0.0000137307,0.9063709,0.0005411336],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004972411,0.9962471,0.00001455748,0.00006815998,0.0002753513,0.001844735,0.0004255324,0.0000422667,0.001032627],"genre_scores_gemma":[0.00001085426,0.991547,0.00002722185,0.0008173814,0.0003965084,0.0006779989,0.003600842,0.00006566995,0.002856457],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7663556,"threshold_uncertainty_score":0.999648,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3132376226","doi":"10.1007/s40259-020-00464-5","title":"Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists","year":2021,"lang":"en","type":"article","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Janssen UK; Arthritis Society; Psoriasis Association","keywords":"Medicine; Nice; Specialty; Excellence; Equity (law); Alternative medicine; Health care; Family medicine; Intensive care medicine; Political science","retraction":null,"screen_n_in":null,"score":{"opus":0.04720052022437258,"gpt":0.3089021478445579,"spread":0.2617016276201853,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001252075,0.0003775535,0.0009630266,0.0001598542,0.0001761449,0.00004694411,0.0003194351,0.0007172086,0.0001016767],"category_scores_gemma":[0.001126443,0.0003166717,0.0001785193,0.0002503299,0.001527047,0.00007271702,0.0002726402,0.0004537317,0.00002307599],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006049621,"about_ca_system_score_gemma":0.0001862914,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004682147,"about_ca_topic_score_gemma":0.0008292862,"domain_scores_codex":[0.9953873,0.00195701,0.001154322,0.0007967011,0.00005563441,0.0006490974],"domain_scores_gemma":[0.9980751,0.0007221359,0.0004266957,0.0005213159,0.0001774813,0.00007725311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006509694,0.0004283352,0.9827083,0.00002941723,0.0002131118,0.0002008029,0.000238367,0.00003218169,0.007272831,0.00143687,0.0002372333,0.00655157],"study_design_scores_gemma":[0.005753619,0.0006271364,0.9757103,0.0001943313,0.0001023676,0.000843084,0.001510526,0.00007614058,0.01270896,0.0001863515,0.001878765,0.0004083576],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931176,0.00456163,0.0001493351,0.0002404441,0.001014067,0.0002502192,0.0002393012,0.0001003857,0.0003269992],"genre_scores_gemma":[0.9961526,0.0009103371,0.002182173,0.0001074764,0.00003572826,0.00001741567,0.0005083261,0.00001824276,0.00006765497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006997954,"threshold_uncertainty_score":0.9999285,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2302684203","doi":"10.1007/s40259-016-0166-5","title":"Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Panitumumab; KRAS; Cetuximab; Neuroblastoma RAS viral oncogene homolog; Colorectal cancer; Targeted therapy; Medicine; Oncology; Epidermal growth factor receptor; Oncogene; Cancer; Cancer research; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.05484679178644022,"gpt":0.3942189056036,"spread":0.3393721138171598,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002617885,0.0003019612,0.001936468,0.0002355808,0.00006540382,0.00001104616,0.0001392007,0.00007572517,0.0002420726],"category_scores_gemma":[0.00003791196,0.0001374595,0.000914505,0.0007204869,0.0001109963,0.00002369815,0.00001964917,0.0001126751,0.000004116478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002021203,"about_ca_system_score_gemma":0.0004397452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001820517,"about_ca_topic_score_gemma":0.0001474956,"domain_scores_codex":[0.9985371,0.0001133757,0.0005190035,0.0003303284,0.0002855021,0.0002146674],"domain_scores_gemma":[0.9988355,0.0004757807,0.0003272228,0.0001961011,0.0001299355,0.00003548398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001791637,0.000264602,0.0001916653,0.001227811,0.00784893,0.00001655969,0.0004717959,5.201361e-7,0.000009340266,0.00003809501,0.0002701738,0.9894813],"study_design_scores_gemma":[0.005049576,0.00102582,0.02134733,0.003912456,0.02214683,0.00004163863,0.0002362757,0.00001742614,0.0001325023,0.0001103967,0.9454806,0.0004991097],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003347244,0.9925677,0.00002555319,0.0003412059,0.000119362,0.00191964,0.001532434,0.000009722681,0.0001371625],"genre_scores_gemma":[0.006017216,0.9917307,0.0002118959,0.00008179113,0.0001179148,0.001395431,0.0002800415,0.00002318277,0.0001417751],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9889823,"threshold_uncertainty_score":0.5605435,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4411046742","doi":"10.1007/s40259-025-00727-z","title":"Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings","year":2025,"lang":"en","type":"review","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Arthritis Research Centre of Canada","funders":"Sandoz; Diakonhjemmet","keywords":"Biosimilar; Real world evidence; Intensive care medicine; Medicine; Pharmacotherapy; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1159401178690415,"gpt":0.3997444058284289,"spread":0.2838042879593874,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007371716,0.0003987029,0.00194525,0.0004739385,0.00007036121,0.0000122475,0.0002778539,0.000959281,0.00007835758],"category_scores_gemma":[0.0004562026,0.0002972474,0.0004240191,0.0007631338,0.0004443775,0.00002609701,0.0002326535,0.0007715413,0.00001785853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000452671,"about_ca_system_score_gemma":0.0002038523,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003608736,"about_ca_topic_score_gemma":0.00007911806,"domain_scores_codex":[0.9967851,0.0007097952,0.001471276,0.0006346775,0.00005333255,0.000345832],"domain_scores_gemma":[0.99705,0.001891808,0.000481796,0.0004577587,0.00007397722,0.00004468493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002840284,0.0002308131,0.0007364391,0.00225194,0.0001958949,0.000002001748,0.00002302823,5.997183e-8,0.000003821516,0.003260627,0.01618242,0.9770846],"study_design_scores_gemma":[0.0003884755,0.0002193974,0.001663093,0.009563596,0.0004703543,0.000002732951,0.00001552055,2.494231e-7,0.00007370167,0.0001221054,0.9872003,0.0002804573],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001594966,0.9934868,8.380548e-7,0.0008718774,0.0007885649,0.0009201423,0.0009227095,0.00002696558,0.002822669],"genre_scores_gemma":[0.00002715075,0.9965358,0.0006684523,0.00130594,0.00002601024,0.00005663536,0.0001721927,0.00001848271,0.00118934],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9768041,"threshold_uncertainty_score":0.999948,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4407922422","doi":"10.1007/s40259-025-00709-1","title":"Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries","year":2025,"lang":"en","type":"article","venue":"BioDrugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia Hospital; University of Calgary; University of British Columbia; University of Toronto; Providence Health Care","funders":"Canadian Institutes of Health Research; National Research Foundation of Korea; Michael Smith Health Research BC","keywords":"Biosimilar; Infliximab; Adalimumab; Etanercept; Descriptive statistics; Medicine; Antirheumatic Agents; Pharmacology; Business; Rheumatoid arthritis; Internal medicine; Tumor necrosis factor alpha","retraction":null,"screen_n_in":null,"score":{"opus":0.01123814212673292,"gpt":0.2880359146218365,"spread":0.2767977724951036,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004691872,0.0002334813,0.0005696196,0.000776,0.00009344663,0.00003705748,0.00008382883,0.0002784346,0.0001376745],"category_scores_gemma":[0.0002004188,0.0001509109,0.0000957423,0.0005050123,0.0006883396,0.00006627827,0.0000836208,0.0001400936,0.000001068642],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005117812,"about_ca_system_score_gemma":0.00007136162,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001386874,"about_ca_topic_score_gemma":0.0003628377,"domain_scores_codex":[0.998789,0.0003300955,0.0003008338,0.0003005375,0.00003090783,0.0002485908],"domain_scores_gemma":[0.998938,0.0007070329,0.00009545024,0.0001813733,0.00004664986,0.00003145222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007057009,0.0006897164,0.6305608,0.0005742905,0.008819886,0.000007587357,0.01187592,0.00001037097,0.2441719,0.01337747,0.005446977,0.0774081],"study_design_scores_gemma":[0.00104005,0.0003201232,0.8635598,0.0001392185,0.0006153382,0.000008436791,0.002380715,0.000201898,0.1281869,0.0008623166,0.002391553,0.000293635],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990145,0.005304493,0.00004101775,0.002436612,0.0000334448,0.0001799303,0.0003159822,0.0000162514,0.001527306],"genre_scores_gemma":[0.9970738,0.001939933,0.0001221055,0.0004950829,0.000008718791,0.000008715795,0.000006563236,0.000005706371,0.000339334],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2329991,"threshold_uncertainty_score":0.6153967,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4362507438","doi":"10.1007/s40259-023-00592-8","title":"Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor","year":2023,"lang":"en","type":"article","venue":"BioDrugs","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"ZonMw","keywords":"Medicine; Internal medicine; Rheumatoid arthritis; Etanercept; Cohort; Adverse effect; Adalimumab; Infliximab; Rituximab; Discontinuation; Disease; Pediatrics","retraction":null,"screen_n_in":null,"score":{"opus":0.1220145560077484,"gpt":0.3517712687053033,"spread":0.229756712697555,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003112016,0.0001548153,0.0002070813,0.00005934744,0.0001627498,0.00007259932,0.0003147667,0.00009709376,0.0005391389],"category_scores_gemma":[0.0005214656,0.00008971994,0.00006109607,0.0003475636,0.0001806969,0.0001109032,0.0002645427,0.0001927923,0.0005378461],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001885659,"about_ca_system_score_gemma":0.0000987998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001663637,"about_ca_topic_score_gemma":0.00005450581,"domain_scores_codex":[0.9985098,0.0001193173,0.0003285002,0.0004279712,0.0002723099,0.0003421289],"domain_scores_gemma":[0.9985015,0.0002482068,0.00008833934,0.0009625363,0.00007525338,0.0001241548],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001713035,0.0003859519,0.6845701,0.00004512414,0.0007007376,0.001363262,0.001781712,9.237416e-7,0.01930305,0.000124862,0.07322718,0.2167841],"study_design_scores_gemma":[0.002593655,0.001380536,0.6168689,0.0005289889,0.00003109305,0.000119237,0.004042661,0.0005763346,0.01090655,0.001260482,0.3611286,0.0005629787],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895579,0.00464187,0.00001043217,0.003918819,0.0003612549,0.0004438906,0.000387527,0.0002265119,0.0004517584],"genre_scores_gemma":[0.9926283,0.004639958,0.0002174455,0.0003197661,0.0002419555,0.00009387243,0.001649555,0.00001413068,0.0001949928],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2879014,"threshold_uncertainty_score":0.6913103,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2007886942","doi":"10.2165/00063030-200013040-00004","title":"Use of Thalidomide in Dermatological Indications","year":2000,"lang":"en","type":"article","venue":"BioDrugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Thalidomide; Medicine; Adverse effect; Immunology; Pharmacology; Drug; Disease; Internal medicine; Multiple myeloma","retraction":null,"screen_n_in":null,"score":{"opus":0.07712116623729452,"gpt":0.3360419291086052,"spread":0.2589207628713107,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004058333,0.00004948273,0.0001327675,0.00008636543,0.00001718956,0.000004627775,0.00003679386,0.00004432488,0.001052629],"category_scores_gemma":[0.00007997454,0.0000355864,0.00003671761,0.0001549359,0.00006269548,0.00004099874,0.000009894226,0.00006239244,0.0002012155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002250302,"about_ca_system_score_gemma":0.00004281127,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002079203,"about_ca_topic_score_gemma":0.0000165417,"domain_scores_codex":[0.9994633,0.00003211758,0.0001397763,0.00009774783,0.0001295402,0.000137582],"domain_scores_gemma":[0.9996533,0.00007248665,0.00001748213,0.0001527925,0.00001703535,0.00008684253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002725813,0.0005583224,0.9674388,0.00002135501,0.00003428413,0.0001412621,0.0001489108,0.000001081576,0.001083384,0.0002625119,0.0007218084,0.02931572],"study_design_scores_gemma":[0.00163615,0.00005314669,0.9810886,0.00003371221,0.000010772,0.0000419839,0.00002176835,0.0001040046,0.006309905,0.00005166621,0.01060881,0.00003942905],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950683,0.0000935002,0.000002830863,0.0007926782,0.000005696573,0.0002126592,0.00001618009,0.0000150609,0.00379316],"genre_scores_gemma":[0.9978416,0.000129344,0.00104279,0.0001043079,0.000007814808,0.00002014261,0.000036178,0.0000036497,0.0008141625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02927629,"threshold_uncertainty_score":0.9998605,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4200032396","doi":"10.1007/s40259-021-00512-8","title":"A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn’s Disease","year":2021,"lang":"en","type":"article","venue":"BioDrugs","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"UCB Pharma; National Institute of Diabetes and Digestive and Kidney Diseases","keywords":"Certolizumab pegol; Medicine; Calprotectin; Internal medicine; Confidence interval; Crohn's disease; Odds ratio; Area under the curve; Population; Placebo; Gastroenterology; Pharmacokinetics; Inflammatory bowel disease; Disease; Adalimumab","retraction":null,"screen_n_in":null,"score":{"opus":0.03376399519034329,"gpt":0.3145580637676515,"spread":0.2807940685773082,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002468703,0.000139435,0.0001646649,0.00003682415,0.00004932295,0.00001365086,0.0001553776,0.0001107834,0.00001210653],"category_scores_gemma":[0.001976187,0.0001438415,0.0002222027,0.00007552138,0.00005306579,0.00000401689,0.0001692062,0.00003982801,0.00001036064],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003206934,"about_ca_system_score_gemma":0.0006796489,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001495519,"about_ca_topic_score_gemma":0.00001651341,"domain_scores_codex":[0.9985212,0.0001634947,0.0004258075,0.0005266243,0.0001387431,0.0002241388],"domain_scores_gemma":[0.998418,0.00003590234,0.00006614794,0.0006922411,0.0003466871,0.0004410698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.1434069,0.001947634,0.06801974,0.0007366827,0.0001892112,0.000712991,0.0004485545,0.003105524,0.7435599,0.000174829,0.02514431,0.01255374],"study_design_scores_gemma":[0.003437418,0.0006445666,0.9121736,0.00008092615,0.0001540504,0.00001910549,0.00005335797,0.009137499,0.05619022,0.0005131777,0.01705116,0.0005449032],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910479,0.00004000345,0.006006587,0.0008268764,0.0001525479,0.0008748297,0.0009902732,0.000018881,0.00004216904],"genre_scores_gemma":[0.9915343,0.000004500732,0.006704502,0.0003386119,0.0001639695,0.000262435,0.0001231475,0.00002219661,0.0008463734],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8441539,"threshold_uncertainty_score":0.5865686,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}